Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Heptares Pharma

- PMLiVE

FDA approves Alvotech and Teva’s Simlandi as interchangeable Humira biosimilar

Simlandi is approved to treat multiple indications, including rheumatoid arthritis and Crohn’s disease

- PMLiVE

Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray

Royalty Pharma signed a deal for the programme in 2020 with Biohaven, which Pfizer has since acquired

- PMLiVE

Teva and Allergan finalise terms of US opioid settlements worth $6.6bn combined

Nearly 500,000 died from an opioid overdose between 1999 and 2019

- PMLiVE

Pfizer to acquire Biohaven in deal worth over $11bn

The deal will expand Pfizer’s Internal Medicine pipeline

- PMLiVE

Teva reaches $925,000 settlement to resolve drug price-fixing claims

Last year, the US Department of Justice charged Teva for conspiring with competitors in a generic drug price-fixing probe

- PMLiVE

Pfizer, Sanofi and others set to increase US drug prices in 2021

Pressure from COVID-19 restrictions leads to drug price increases

Infographic

Migraine market snapshot

Research Partnership

- PMLiVE

US charges Teva for generic drug price-fixing plot

Company maintains it has not committed any wrongdoing

- PMLiVE

Biohaven gets FDA approval for migraine drug Nurtec ODT

Becomes second drugmaker to bring an oral CGRP inhibitor to US market

- PMLiVE

Teva’s weak pipeline hit by Tourette’s drug trial failure

Drug wasn't able to improve on placebo

- PMLiVE

Lilly launches migraine med Reyvow at $640 per eight-pill pack

Enters increasingly competitive market

- PMLiVE

Eli Lilly scores positive phase 3 results for Emgality in treatment resistant migraine

Hopes to catch up with rivals in the market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links